Skip to main content



Research Website | Addiction Clinical Trials

Research Interests

Dr. Garbutt is an Adjunct Professor of Psychiatry who directed the Addiction Clinical Trials program before his retirement in 2019.  Dr. Garbutt has been involved in multiple clinical trials for alcohol use disorders including studies of long-acting naltrexone, oxytocin and baclofen.  Dr. Garbutt remains active as a consultant to the ACT program and is confident that clinical research will continue to expand the treatment options available to patients with substance use disorders.

Visit the ACT website for additional information.

Recent Publications

Click here for a list of publications from PubMed

Implementation of a Process for Initiating Naltrexone in Patients Hospitalized for Alcohol Detoxification or Withdrawal. Stephens JR, Moore C, Stepanek KV, Garbutt JC, Starke B, Liles A, Jonas DE. J Hosp Med. 2018 Jan 24:E1-E8. doi: 10.12788/jhm.2900. PMID: 29364992

Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial. Garbutt JC, Kampov-Polevoy AB, Kalka-Juhl LS, Gallop RJ. JAMA Psychiatry. 2016 Oct 1;73(10):1056-1063. doi: 10.1001/jamapsychiatry.2016.2157. PMID:27627782

Alcohol Use Disorder Treatment: The Association of Pretreatment Use and the Role of Drinking Goal. Berger L, Brondino M, Fisher M, Gwyther R, Garbutt JC. J Am Board Fam Med. 2016 Jan-Feb;29(1):37-49. doi: 10.3122/jabfm.2016.01.150143. PMID:26769876

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. Jonas DE, Amick HR, Feltner C, Wines R, Shanahan E, Rowe CJ, Garbutt JCPharmacogenomics. 2014 Sep;15(13):1687-700. doi: 10.2217/pgs.14.121. Review. PMID:25410894

Medications for alcohol use disorders–reply. Jonas DE, Feltner C, Garbutt JCJAMA. 2014 Oct 1;312(13):1351. doi: 10.1001/jama.2014.10170. No abstract available. PMID:25268447